Neovasc, an OPKO Supported Company, Reports That Reducer™ Achieves Primary Endpoint in COSIRA Trial, Significantly Improving Function in Patients with Refractory Angina Nov 6, 2013
OPKO Commences Pivotal Clinical Validation Study for 4Kscore™ as a Predictor of Prostate Cancer Prior to Biopsy Nov 4, 2013
OPKO Adds to Growing Technology Portfolio Through Strategic Investment in Biotechnology Company Engaged in the Development of a New Generation of Antibodies Oct 10, 2013
